UK Non Invasive Prenatal Testing Market Size & Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non invasive prenatal testing market will help companies and investors design strategic landscapes.

13-24 weeks was the largest segment with a revenue share of 51.46% in 2022. Horizon Databook has segmented the UK non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.

NIPT is approved by the UK Genetic Testing Network only for certain specific conditions. Only high-risk pregnant women are offered NIPT, for example, women who have an indication or family history of abnormalities. Moreover, NIPT is a safer option when compared to invasive tests. NIPT was first offered in the country in 2012. NIPT was implemented in England in July 2021, in Scotland in September 2020, and in Wales in April 2018. The growing demand for NIPT in the region can be attributed to the ease of making informed decisions post the test for management of pregnancy. In addition, in 2016, the UK National Screening Committee suggested an approach that pregnant women with over one in 150 having a chance of aneuploidy development should be offered NIPT. 

Private clinics and individual clinicians are delivering NIPT supplied by a variety of different laboratories, based in the UK and overseas. Testing cannot be done direct-to-consumer; it must be done by a medical professional. Moreover, recent technological improvements in approvals are driving market growth. For instance, in 2019, the UK NSC approved the procurement of NGS and microarray for the provision of NIPT. In March 2019, Horizon Discovery Group plc collaborated with the European Molecular Genetics Quality Network and St George's University Hospital for development of reference material for NIPT solutions. Such developments are anticipated to drive the commercialization of tests in the country.